University of Illinois Hospitals and Clinics (UI Health)
Chicago, Illinois, 60608, United States
Location contact
Neeraj Chhabra, MD
CONTACT
Niranjan S. Karnik, MD, PhD
CONTACT
NCT Number: NCT07498322
This study, called the Chicago Data-driven Opioid use disorder Screening, Engagement, Treatment and Planning (C-DOSETaP) System, tests a new system of clinical care for patients with opioid use disorder (OUD) across a large health system.
The main questions this study aims to answer are:
1. Does the C-DOSETaP System increase screening for patients with OUD; 2. Does the C-DOSETaP System improve continuity of health care for patients with OUD; 3. Does the C-DOSETaP System increase use of medications for opioid use disorder; and 4. Does the C-DOSETaP System reduce the number of opioid-related deaths in the neighborhoods served.
Trial opening soon.
Get Notified16 year and older
All sexes
Interventional
Not applicable
Chicago, Illinois, 60608, United States
Neeraj Chhabra, MD
CONTACT
Niranjan S. Karnik, MD, PhD
CONTACT
The Chicago Data-driven Opioid use disorder Screening, Engagement, Treatment and Planning (C-DOSETaP) System, tests an innovative approach leveraging healthcare data harmonization, digital tools, and clinical workflows to improve the care for patients with opioid use disorder (OUD) across a large health system serving a population heavily affected by the opioid overdose epidemic. The C-DOSETaP system will implement a diverse set of screening tools across the health systems' numerous clinical domains, improve healthcare engagement and utilization of OUD treatments, and pursue a data-forward approach leveraging electronic health record (EHR) data to track care delivery and engage with patients at risk for treatment dropout or failure.
The investigators hypothesize that implementation of the C-DOSETaP system alongside a locally developed system-level opioid response plan will result in: 1) increased OUD screening rates; 2) improved continuity of care; 3) increased utilization of medications for opioid use disorder (MOUD); and 4) reduced mortality in neighborhoods served by the primary study institution.
Primary Outcomes Three dimensions of OUD treatment and engagement will be assessed as primary outcomes for the study. The investigators will measure: 1) screening rates; 2) continuity of care; and 3) use of MOUD across the health system. Screening rates will be measured as the proportion of all patients with encounters in the health system that have a completed screening for opioid misuse within the preceding 12 months. Continuity of care will be assessed by appointment follow-up and completed referral to the next care site. Use of MOUD will be measured as the number of patients actively on MOUD as a proportion of all patients with documented OUD within the health system as defined by International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes.
Secondary Outcomes The investigators plan to evaluate aggregate impact of interventions and primary measures on OUD mortality reported in neighborhoods served by the primary study institution during the phased stepped wedge rollout across system-associated clinics. The secondary outcomes for this phase include quarterly opioid-related mortality by zip codes served by the primary institution.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Completed screening for opioid use disorder
Medication treatment for opioid use disorder
Facilitation of outpatient treatment linkages
Time frame: Rolling measure of annual rates (12 months) measured over the implementation period.
Aggregate rate of data-driven OUD screening across the health system
Time frame: 30 days and 12 months
Continuity of care will be assessed through appointment follow-up and completion of referral to the next care site within 30 days.
Time frame: Baseline and 12 months
MOUD use will be measured as the number of patients actively on MOUD as a proportion of all patients within the health system and of those with documented OUD within the health system as defined by International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes.
Time frame: Baseline and 12 months
Quarterly opioid-related mortality rate by zip codes served by the primary institution reported to the Illinois Department of Public Health
Time frame: Baseline and 12 months
Quarterly opioid-related screening rates by zip codes served by the primary institution reported to the Illinois Department of Public Health
Time frame: Baseline and 12 months
Quarterly MOUD utilization rates by zip codes served by the primary institution reported to the Illinois Department of Public Health
Contact information is provided by the study sponsor or research team.
Neeraj Chhabra, MD
CONTACT
Niranjan S. Karnik, MD, PhD
CONTACT
University of Illinois at Chicago
Other
Acronym: C-DOSETaP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07457489
Chemically-Induced Disorders, Mental Disorders
Brentwood, Tennessee, United States
View Trial DetailsNCT07085351
Chemically-Induced Disorders, Mental Disorders
Chicago, Illinois, United States
View Trial DetailsNCT05304364
Behavior, Behavior, Addictive
Adelaide, South Australia, Australia
View Trial DetailsNCT03831971
Behavior, Behavior, Addictive
Bethesda, Maryland, United States
View Trial Details